Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer ...

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

Liz Nichols is a construction worker and artist in Portland, Ore. She posts poems and art on Instagram @graydaygoods.

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Around 100 participants with type 2 diabetes mellitus will be enrolled across US sites.

Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...